Evidence map›Paper›PMID 32287402›Full record

ReviewPediatria polska

Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Leonard Both, Ashley C Banyard, Craig van Dolleweerd, Edward Wright, Julian K-C Ma, Anthony R Fooks

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatria polska. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leonard BothThe Hotung Molecular Immunology Unit, Division of Clinical Sciences, St George's, University of London, London, UK.
Ashley C BanyardAnimal Health and Veterinary Laboratories Agency (AHVLA), Wildlife Zoonoses and Vector-borne Diseases Research Group, Department of Virology, Weybridge, Surrey, UK.
Craig van DolleweerdThe Hotung Molecular Immunology Unit, Division of Clinical Sciences, St George's, University of London, London, UK.
Edward WrightSchool of Life Sciences, University of Westminster, London, UK.
Julian K-C MaThe Hotung Molecular Immunology Unit, Division of Clinical Sciences, St George's, University of London, London, UK.
Anthony R FooksAnimal Health and Veterinary Laboratories Agency (AHVLA), Wildlife Zoonoses and Vector-borne Diseases Research Group, Department of Virology, Weybridge, Surrey, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable.

Indexed as

Antibody engineeringAntiviral immunityMonoclonal antibodySerum therapy

Identifiers

PMID32287402
PMCPMC7111719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.